title: Heparin-associated thrombocytopenia: the antibody is not heparin specific.
abstract: In this study the hypothesis was assessed whether heparin-associated thrombocytopenia (HAT) may be caused by an antibody dependent on polysulfated oligosaccharide epitopes, present not only on heparin but also on different polysulfated substances such as dextran sulfate and pentosan polysulfate. We found that the major factor for eliciting platelet activation with sera of HAT type II patients is neither the structure nor the AT III binding capacity of an oligosaccharide, but rather its grade of sulfation. This was shown by in vitro crossreactivity studies with 40 sera of HAT type II patients using unfractionated heparins, LMW heparins (Fragmin, Fraxiparin), enoxaparin, LMW heparinoid (Org 10172 and its subfractions), de-N-sulfated heparin, dermatan sulfate, dextran sulfate, pentosan polysulfate and dextran. Platelet activation was measured by the heparin induced platelet activation (HIPA) assay and the serotonin release assay (SRA). The platelet activating factor was isolated with the IgG fraction, but did not bind to heparin and dextran sulfate fixed to a solid phase. By isoimmune fixation electrophoresis a monoclonal gammopathy was ruled out in the three sera assessed. The in vivo effect of different LMW heparins and the heparinoid Org 10172 was observed in 10 patients with HAT type II. In a prospective study, a compatible heparin-like anticoagulant was selected for 10 HAT patients for whom further parenteral anticoagulation was required. The only substance that showed no crossreactivity in vitro was the LMW heparinoid Org 10172, which differs from heparin and LMW heparins by its low-grade sulfation. Upon treatment with the heparinoid, all 10 patients had a good clinical outcome, even if they had previously developed thromboembolic complications under LMW heparin administration.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University Giessen, FRG.
authors.forename: A
authors.initials: A
authors.lastname: Greinacher
authors.forename: I
authors.initials: I
authors.lastname: Michels
authors.forename: C
authors.initials: C
authors.lastname: Mueller-Eckhardt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000918:Antibody Specificity / Q000276:immunology; D005260:Female; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects* / Q000276:immunology; D011446:Prospective Studies; D013431:Sulfates; D013921:Thrombocytopenia / Q000139:chemically induced / Q000150:complications / Q000276:immunology*; D013923:Thromboembolism / Q000188:drug therapy*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D007074:Immunoglobulin G; D013431:Sulfates; D006493:Heparin